PrEP (pre-exposure prophylaxis) is a new HIV prevention intervention. PrEP Watch is a clearinghouse for PrEP data, additional research, cost, access and advocacy efforts across the globe.
Communities across the globe are at varying stages of implementation of daily oral PrEP. TDF/FTC is approved for use as oral PrEP in a handful of countries, and access is expanding globally. In some places there is growing uptake; in others, access is limited to pilot projects. Other countries are not yet exploring implementation. Learn more about access and advocacy below.
Daily oral PrEP involves drugs that are also used in HIV treatment. This means the strategy may only be available via off-label use in some places. Much work is needed to see innovative, impactful introduction.
January 11, 2016
December 4, 2015
This report includes a discussion of the research to date on the safety of PrEP use among transgender women, guidance for clinicians on prescribing PrEP to transgender women and recommendations for more intensive research on HIV prevention technologies for transgender women.
December 3, 2015
1 in 4 people living with HIV in the United States are women. This article from the mainstream US press (a website called Refinery 29) explores why more women aren’t talking about PrEP—despite the fact that it's been FDA-approved since 2012— and the potential PrEP has to improve women’s health.